Chairman & Officer Files Intent to Sell $1.27M in Shares Following Recent RSU Vesting and FDA Approval
VNDA has more than doubled off its 52-week low of $3.809.
Summary
Vanda Pharmaceuticals' Chairman and Officer, Mihael H. Polymeropoulos, filed an intent to sell $1.27 million worth of shares, acquired from RSU vesting, shortly after the company received FDA approval for a new drug.
Key Events · Ownership and Investor Activity · VNDA
-
Key Executive Files Intent to Sell
Mihael H. Polymeropoulos, Chairman of the Board and an Officer, filed a Form 144 to sell 156,235 shares of common stock.
-
Significant Transaction Value
The proposed sale has an approximate market value of $1,276,976.00.
-
Shares from RSU Vesting
The shares intended for sale were acquired on March 1, 2026, through the vesting and settlement of Restricted Stock Units (RSUs) as compensation.
-
Timing Post-FDA Approval
This intent to sell follows the company's announcement of FDA approval for BYSANTI™ on February 23, 2026, a significant positive development.
Analysis · VNDA · Life Sciences
Mihael H. Polymeropoulos, the Chairman of the Board and an Officer, has filed a Form 144 indicating an intent to sell 156,235 shares of common stock, valued at approximately $1.27 million. These shares were acquired through the vesting and settlement of Restricted Stock Units (RSUs) on March 1, 2026. This significant insider selling intent, representing a notable portion of the company's market capitalization, comes shortly after the company announced FDA approval for BYSANTI™ on February 23, 2026, a major positive catalyst. While the sale is tied to compensation vesting, the timing of a key executive filing an intent to sell after such positive news could be viewed negatively by investors, adding to a recent pattern of insider distribution.
How filings like this one have moved
In the 30 days to Sep 20, 2026, 34.7% of the 1039 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.43%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VNDA was trading at $8.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $482.9M. The 52-week trading range was $3.81 to $9.60. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.